Papers/PMID:26834458
Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials.
Drug design, development and therapy2016The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
quetiapine — increases withdrawal due to adverse events
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“The rates of pooled overall discontinuation and discontinuation due to adverse events of quetiapine-XR were greater than placebo.”
Quoted verbatim from Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- Adults with generalized anxiety disorder, pooled from three randomized controlled trials of quetiapine-XR
Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials.2016PMID:26834458Permalink